{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:29:26Z","timestamp":1790231366417,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T00:00:00Z","timestamp":1503100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11914-017-0401-0","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T06:15:10Z","timestamp":1503123310000},"page":"412-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"15","author":[{"given":"A.","family":"Biggin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F.","family":"Munns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,19]]},"reference":[{"issue":"3","key":"401_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11914-014-0225-0","volume":"12","author":"A Biggin","year":"2014","unstructured":"Biggin A, Munns CF. Osteogenesis imperfecta: diagnosis and treatment. Curr Osteoporos Rep. 2014;12(3):279\u201388.","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"401_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03008209509010818","volume":"31","author":"PH Byers","year":"1995","unstructured":"Byers PH. Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses. Connect Tissue Res. 1995;31(4):257\u20139.","journal-title":"Connect Tissue Res"},{"issue":"10028","key":"401_CR3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657\u201371.","journal-title":"Lancet"},{"issue":"2","key":"401_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316.","journal-title":"J Med Genet"},{"issue":"12","key":"401_CR5","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","volume":"27","author":"P Trejo","year":"2016","unstructured":"\u2022\u2022 Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int. 2016;27(12):3427\u201337. A recent review of the diagnosis and management of OI in children including new approaches to treatment.","journal-title":"Osteoporos Int"},{"issue":"12","key":"401_CR6","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","volume":"167A","author":"L Bonafe","year":"2015","unstructured":"Bonafe L, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869\u201392.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"401_CR7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skelet Radiol. 1987;16(5):360\u20133.","journal-title":"Skelet Radiol"},{"key":"401_CR8","first-page":"CD005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"\u2022\u2022 Dwan K, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. A Cochrane review of 14 trials (819 participants) to assess the effectiveness and safety of bisphosphonates in increasing bone mineral density, reducing fractures and improving clinical function in children and adults with OI.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"401_CR9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","volume":"27","author":"NB Watts","year":"1998","unstructured":"Watts NB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin N Am. 1998;27(2):419\u201339.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"9","key":"401_CR10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc Mayo Clin. 2008;83(9):1032\u201345.","journal-title":"Mayo Clin Proc Mayo Clin"},{"issue":"1","key":"401_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","volume":"51","author":"H Castillo","year":"2009","unstructured":"Castillo H, Samson-Fang L. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009;51(1):17\u201329.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"401_CR12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2003;18(1):126\u201330.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"5\u20136","key":"401_CR13","first-page":"485","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab: JPEM. 2012;25(5\u20136):485\u201391.","journal-title":"J Pediatr Endocrinol Metab: JPEM"},{"issue":"1","key":"401_CR14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","volume":"25","author":"N Bishop","year":"2010","unstructured":"Bishop N, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2010;25(1):32\u201340.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"key":"401_CR15","unstructured":"\u2022 Bishop N, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. The Lancet. 2013; Reported that oral risedronate increased areal BMD and reduced risk of first and recurrent clinical fractures in children with OI."},{"issue":"2","key":"401_CR16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","volume":"21","author":"G Chevrel","year":"2006","unstructured":"Chevrel G, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2006;21(2):300\u20136.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"1","key":"401_CR17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2006;21(1):132\u201340.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"5","key":"401_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2005;20(5):758\u201363.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"6","key":"401_CR19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2005;20(6):977\u201386.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"7","key":"401_CR20","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Mineral Res: Off J Am Soc Bone Mineral Res. 2009;24(7):1282\u20139.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"issue":"9419","key":"401_CR21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363(9419):1427\u201331.","journal-title":"Lancet"},{"issue":"6","key":"401_CR22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25(6):786\u201391.","journal-title":"J Pediatr Orthop"},{"issue":"5","key":"401_CR23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/adc.2007.125468","volume":"93","author":"S Senthilnathan","year":"2008","unstructured":"Senthilnathan S, Walker E, Bishop NJ. Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child. 2008;93(5):398\u2013400.","journal-title":"Arch Dis Child"},{"issue":"2","key":"401_CR24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96(2):355\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"401_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000351374","volume":"79","author":"MB Alcausin","year":"2013","unstructured":"\u2022 Alcausin MB, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333\u201340. Reported that pamidronate started under three years of age improved bone density, reduced fracture frequency and resulted in attainment of motor milestones at an earlier age.","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"401_CR26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, et al. Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res. 2015;30(12):2150\u20137.","journal-title":"J Bone Miner Res"},{"key":"401_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","volume":"86","author":"A Sato","year":"2016","unstructured":"Sato A, et al. Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2 mutations\u2014genotype-phenotype correlations and effect of bisphosphonate treatment. Bone. 2016;86:53\u20137.","journal-title":"Bone"},{"issue":"3","key":"401_CR28","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","volume":"23","author":"CG Shi","year":"2016","unstructured":"Shi CG, Zhang Y, Yuan W. Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther. 2016;23(3):e894\u2013904.","journal-title":"Am J Ther"},{"issue":"5","key":"401_CR29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, et al. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30(5):929\u201333.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"401_CR30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","volume":"41","author":"CF Munns","year":"2007","unstructured":"Munns CF, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41(3):366\u201370.","journal-title":"Bone"},{"issue":"2","key":"401_CR31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00223-015-0021-6","volume":"97","author":"E Brizola","year":"2015","unstructured":"Brizola E, Shapiro JR. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions. Calcif Tissue Int. 2015;97(2):101\u20133.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"401_CR32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.c.31532","volume":"172","author":"R Marom","year":"2016","unstructured":"Marom R, et al. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J Med Genet C Semin Med Genet. 2016;172(4):367\u201383.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"401_CR33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol: Off J Eur Soc Med Oncol\/ESMO. 2006;17(6):897\u2013907.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"4","key":"401_CR34","first-page":"143","volume":"65","author":"Italian Society of Osteoporosis, M.M","year":"2013","unstructured":"Italian Society of Osteoporosis, M.M, et al. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013;65(4):143\u201366.","journal-title":"Reumatismo"},{"issue":"1","key":"401_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00198-012-2158-8","volume":"24","author":"K Sun","year":"2013","unstructured":"Sun K, et al. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int. 2013;24(1):279\u201386.","journal-title":"Osteoporos Int"},{"key":"401_CR36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","volume":"23","author":"E Barrett-Connor","year":"2012","unstructured":"Barrett-Connor E, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporosis Int. 2012;23:233\u201345.","journal-title":"Osteoporosis Int"},{"issue":"4","key":"401_CR37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.13-0675","volume":"144","author":"A Sharma","year":"2013","unstructured":"Sharma A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates. Chest. 2013;144(4):1311\u201322.","journal-title":"Chest"},{"issue":"2","key":"401_CR38","first-page":"154","volume":"13","author":"R Yachoui","year":"2016","unstructured":"Yachoui R. Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Miner Bone Metab. 2016;13(2):154\u20136.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"4","key":"401_CR39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/sdi.12388","volume":"28","author":"SM Ott","year":"2015","unstructured":"Ott SM. Pharmacology of bisphosphonates in patients with chronic kidney disease. Semin Dial. 2015;28(4):363\u20139.","journal-title":"Semin Dial"},{"issue":"1","key":"401_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/adj.12140","volume":"59","author":"RN Bhatt","year":"2014","unstructured":"\u2022 Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J. 2014;59(1):9\u201319. Reports the pediatric uses and adverse effects of bisphosphonates and provides recommendations on the dental management of children receiving bisphosphonates.","journal-title":"Aust Dent J"},{"key":"401_CR41","doi-asserted-by":"crossref","unstructured":"Bejhed, R.S., M. Kharazmi, and Hallberg, Identification of risk factors for bisphosphonate-associated atypical femoral fractures and osteonecrosis of the jaw in a pharmacovigilance database. Ann Pharmacother, 2016. 50(8): 616\u2013624.","DOI":"10.1177\/1060028016649368"},{"issue":"4","key":"401_CR42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","volume":"4","author":"AA Hennedige","year":"2013","unstructured":"Hennedige AA, et al. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2013;4(4):e1.","journal-title":"J Oral Maxillofac Res"},{"issue":"3","key":"401_CR43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00441-007-0499-y","volume":"330","author":"V Bradaschia-Correa","year":"2007","unstructured":"Bradaschia-Correa V, Massa LF, Arana-Chavez VE. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res. 2007;330(3):475\u201385.","journal-title":"Cell Tissue Res"},{"key":"401_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.004","volume":"94","author":"I Vuorimies","year":"2017","unstructured":"Vuorimies I, et al. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment. Bone. 2017;94:29\u201333.","journal-title":"Bone"},{"issue":"11","key":"401_CR45","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Mineral Res: Off J Am Soc Bone Min Res. 2004;19(11):1779\u201386.","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Min Res"},{"issue":"8","key":"401_CR46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","volume":"30","author":"EA Anam","year":"2015","unstructured":"Anam EA, et al. Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment. J Bone Miner Res. 2015;30(8):1362\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"401_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"401_CR48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","volume":"31","author":"RF Vasanwala","year":"2016","unstructured":"Vasanwala RF, et al. Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating? J Bone Miner Res. 2016;31(7):1449\u201354.","journal-title":"J Bone Miner Res"},{"key":"401_CR49","doi-asserted-by":"crossref","unstructured":"\u2022 Trejo P, et al. Diaphyseal femur fractures in osteogenesis imperfecta: characteristics and relationship with bisphosphonate treatment. J Bone Miner Res. 2016; A recent retrospective study looking at 116 femur fractures in 119 children with OI showed atypical fractures were more closely associated with the severity of OI rather than to bisphosphonate treatment history.","DOI":"10.1002\/jbmr.3071"},{"issue":"3","key":"401_CR50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000355111","volume":"81","author":"A Biggin","year":"2014","unstructured":"Biggin A, et al. Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen. Horm Res Paediatr. 2014;81(3):204\u201310.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"401_CR51","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","volume":"40","author":"F Rauch","year":"2007","unstructured":"Rauch F, et al. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40(4):821\u20137.","journal-title":"Bone"},{"issue":"23","key":"401_CR52","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2146\/ajhp140041","volume":"71","author":"SB Green","year":"2014","unstructured":"Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014;71(23):2029\u201336.","journal-title":"Am J Health Syst Pharm"},{"key":"401_CR53","doi-asserted-by":"publisher","unstructured":"Ashby E, et al. Functional outcome of humeral rodding in children with osteogenesis imperfecta. J Pediatr Orthop. 2016; https:\/\/doi.org\/10.1097\/BPO.0000000000000729 .","DOI":"10.1097\/BPO.0000000000000729"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-017-0401-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:12:09Z","timestamp":1719400329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-017-0401-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,19]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s11914-017-0401-0","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,19]]}}}